Table 2.
Breast cancer relative risk by biomarker level, New York Site of BCFR
| Breast cancer relative risk | ||
|---|---|---|
| ORa (95% CI) | ORb (95% CI) | |
| IGF-1 | ||
| Log-transformed continuous IGF-1 (N = 236) | ||
| 1.19 (0.52, 2.70) | 0.77 (0.26, 2.31) | |
| Median IGF-1 in controls (N = 236) | ||
| < 93.95 ng/mL | Reference | Reference |
| Elevated (≥ 93.95 ng/mL) | 1.46 (0.80, 2.71) | 1.37 (0.66, 2.85) |
| ORa (95% CI) | ORc (95% CI) | |
| Interaction with BOADICEA risk score (N = 231) | ||
| Low IGF-1 (< 93.95), low BOADICEA risk (< 3.4%) (N = 27) | Reference | Reference |
| Elevated IGF-1 (≥ 93.95), low BOADICEA risk (< 3.4%) (N = 48) | 2.49 (0.72, 8.63) | 2.76 (0.64, 11.9) |
| Low IGF-1 (< 93.95), high BOADICEA risk (≥ 3.4%) (N = 81) | 3.23 (0.99, 10.59) | 3.74 (0.99, 14.2) |
| Elevated IGF-1 (≥ 93.95), high BOADICEA risk (≥ 3.4%) (N = 75) | 3.82 (1.20, 12.15)* | 3.92 (1.07, 14.4)* |
| RERI | − 0.90 (− 4.22, 2.41) | − 1.55 (− 5.80, 2.69) |
| p value for interaction | 0.28 | 0.21 |
| ORa (95% CI) | ORb (95% CI) | |
| IGFBP-3 | ||
| Log-transformed continuous IGFBP-3 (N = 236) | ||
| 2.76 (0.84, 9.07) | 4.90 (0.99, 24.1) | |
| Median IGFBP-3 in controls (N = 236) | ||
| < 2009 | Reference | Reference |
| Elevated (≥ 2009) | 1.41 (0.79, 2.51) | 1.62 (0.81, 3.24) |
| ORa (95% CI) | ORc (95% CI) | |
| Interaction with BOADICEA risk score (N = 231) | ||
| Low IGFBP-3 (< 2009), low BOADICEA risk (< 3.4%) (N = 28) | Reference | Reference |
| Elevated IGFBP-3 (≥ 2009), low BOADICEA risk (< 3.4%) (N = 47) | 1.52 (0.48, 4.83) | 2.08 (0.55, 7.92) |
| Low IGFBP-3 (< 2009), high BOADICEA risk (≥ 3.4%) (N = 81) | 2.09 (0.71, 6.13) | 2.26 (0.70, 7.25) |
| Elevated IGFBP-3 (≥ 2009), high BOADICEA risk (≥ 3.4%) (N = 75) | 3.24 (1.09, 9.63)* | 3.47 (1.04, 11.6)* |
| RERI | 0.63 (− 1.50, 2.77) | 0.13 (− 2.60, 2.86) |
| p value for interaction | 0.97 | 0.68 |
Abbreviations: BCFR Breast Cancer Family Registry, CI confidence interval, IGF-1 insulin-like growth factor 1, IGFBP-3 insulin-like growth factor binding protein 3, RERI relative excess risk due to interaction
aConditional logistic regression, unadjusted
bConditional logistic regression, adjusted for age at blood draw, BMI, smoking status, alcohol consumption, menopausal status, continuous BOADICEA score, and opposing biomarker (IGF-1 or IGFBP-3)
cConditional logistic regression, adjusted for age at blood draw, BMI, smoking status, alcohol consumption, menopausal status, and opposing biomarker (IGF-1 or IGFBP-3)
*Statistically significant